Abiraterone Acetate for Advanced Prostate Cancer

Abiraterone acetate is an oral medication that treats prostate cancer by shutting down the body’s production of male hormones, including testosterone, which fuel the growth of prostate tumors. It works differently from older hormone therapies: instead of blocking testosterone at its receptor, abiraterone targets an enzyme called CYP17A1 that sits upstream in the hormone-manufacturing pathway, cutting off androgen production at its source across the adrenal glands, testes, and even within the tumor itself. First developed over roughly two decades at the Institute of Cancer Research in London, it earned regulatory approval and quickly changed the treatment landscape for advanced prostate cancer, extending survival in both early and late stages of the disease.

How Abiraterone Works Inside the Body

Prostate cancer cells rely heavily on androgens to grow and survive. Standard hormone therapy, often called androgen deprivation therapy (ADT), lowers testosterone by signaling the testes to stop producing it. But that does not eliminate androgens entirely. The adrenal glands continue making them, and tumor cells themselves can synthesize small amounts. Those residual androgens are enough to keep many tumors growing, which is why the disease often progresses despite initial hormone treatment.

Abiraterone tackles this problem by blocking CYP17A1, the enzyme responsible for a critical step in androgen production. By inhibiting this enzyme, the drug suppresses androgen synthesis not just in the testes but also in the adrenal glands and within the tumor microenvironment.¹ The result is a much more thorough suppression of the hormones that drive prostate cancer growth.

Abiraterone acetate is actually a prodrug, meaning the tablet you swallow is not the active compound. Once absorbed, it is rapidly converted in the body to abiraterone, which does the heavy lifting. But the story does not end there. Research has shown that abiraterone is further converted into a metabolite called D4A (Δ4-abiraterone), which has its own anti-cancer activity. D4A blocks CYP17A1 and additional steroidogenic enzymes, and it also directly antagonizes the androgen receptor, the protein that androgens bind to in order to turn on tumor-growth genes.² This dual mechanism, blocking both hormone production and the receptor itself through its metabolite, gives abiraterone a broader reach than its label might suggest.³

Why Prednisone Is Always Paired With It

If you look at a prescription for abiraterone, you will almost always see prednisone (or another glucocorticoid like dexamethasone) listed alongside it. This is not optional, and understanding why requires a brief look at what happens when you block CYP17A1 so aggressively.

CYP17A1 is not only involved in making androgens. It also plays a role in producing cortisol, the body’s primary stress hormone. When abiraterone blocks this enzyme, cortisol levels drop. The brain detects low cortisol and responds by ramping up a signaling hormone called ACTH, which in turn drives the adrenal glands to overproduce mineralocorticoids, a different class of steroid hormones that regulate salt and water balance. The consequence is a syndrome of mineralocorticoid excess: fluid retention, high blood pressure, and low potassium.⁴ Early trials that tested abiraterone without glucocorticoid supplementation found that the majority of patients developed these symptoms.

A low dose of prednisone, typically 5 mg twice daily, acts as a cortisol replacement. It satisfies the body’s cortisol needs enough to keep ACTH from surging, preventing the mineralocorticoid overload.⁵ It is essentially the same logic used in other conditions where the adrenal glands cannot produce adequate cortisol on their own.

How Well It Works in Advanced Prostate Cancer

Abiraterone has been tested extensively in two broad patient groups: those whose cancer has stopped responding to standard hormone therapy (castration-resistant prostate cancer, or CRPC) and those who are newly diagnosed with cancer that still responds to hormones but has already spread (castration-sensitive disease). The results in both settings have been strong enough to make it a standard treatment worldwide.

In patients with castration-resistant disease who had not yet received chemotherapy, a landmark trial found that adding abiraterone and prednisone to ongoing ADT improved overall survival compared with prednisone alone, with a hazard ratio of 0.75. In practical terms, patients in the control group had a median survival of about 27 months, while the abiraterone group had not yet reached its median survival at the time of analysis.⁶

The results were even more striking in newly diagnosed castration-sensitive disease. The LATITUDE trial enrolled men with high-risk metastatic cancer and found that adding abiraterone to standard ADT extended median overall survival from about 36.5 months to over 53 months, with a hazard ratio for death of 0.66.⁷ Radiographic progression-free survival, the time before scans showed the cancer growing again, more than doubled from roughly 15 months to 33 months.⁸ A Canadian health technology review confirmed the overall pattern: compared with standard care, abiraterone was associated with longer survival, slower progression, and improved quality of life.⁹

Side Effects and What Gets Monitored

The most characteristic side effects of abiraterone stem from the mineralocorticoid excess described earlier. Even with prednisone on board, some patients experience fluid retention, elevated blood pressure, and low potassium. Low potassium (hypokalemia) deserves particular attention because it can affect heart rhythm and muscle function. A case report in the literature describes a 67-year-old man whose potassium dropped enough to require active management, illustrating why regular blood work is standard practice for anyone taking the drug.¹⁰

Liver function is the other major area of monitoring. In one study of 274 patients, roughly a quarter experienced some degree of liver enzyme elevation within the first six months of treatment. Most of these were mild: about 18% were grade 1 (minor) and only about 1.5% reached grade 3 or 4 (serious). The median time to detect an elevation was around eight weeks, and three-quarters of affected patients continued treatment without interruption, with enzyme levels returning to normal on their own within a few weeks.¹¹ A separate study found similar timing and noted that in over half of patients, liver tests normalized spontaneously even while staying on full-dose abiraterone.¹² Still, because severe liver toxicity is possible, oncology teams typically check liver enzymes every two weeks for the first three months, then monthly thereafter.

Cardiovascular Concerns

The same mineralocorticoid-driven effects that cause fluid retention and high blood pressure also raise questions about the heart. A pharmacovigilance study found that compared with other forms of androgen deprivation therapy, abiraterone was associated with higher rates of reported heart failure and atrial tachyarrhythmias, consistent with its unique mechanism of causing hypokalaemia, hypertension, and edema.¹³ A meta-analysis quantified the overall cardiac risk: the use of newer hormonal agents including abiraterone was tied to roughly a 36% increased risk of all-grade cardiac toxicity and about an 84% increase in high-grade cardiac events. Abiraterone specifically increased the risk of both cardiac toxicity and hypertension, whereas enzalutamide (a related but mechanistically different drug) was linked mainly to hypertension alone.¹⁴

For patients with pre-existing heart conditions, this means careful risk-benefit discussion before starting the drug. It does not automatically disqualify someone, but it does demand vigilant blood pressure management and close follow-up with cardiology when needed.

Abiraterone Versus Enzalutamide

Enzalutamide is the drug most often compared head-to-head with abiraterone. While abiraterone blocks androgen production by inhibiting CYP17A1, enzalutamide works downstream: it binds directly to the androgen receptor, preventing testosterone from activating it. They are sometimes described as working at different points of the same signaling chain.

Two systematic reviews and meta-analyses have compared them. Both found that enzalutamide produced higher PSA response rates, suggesting somewhat better biochemical disease control.¹⁵ But the trade-off was side effects. Both reviews found that enzalutamide carried a higher risk of fatigue, which is a meaningful quality-of-life concern.¹⁶ The reviews differed on overall adverse event rates, with one finding a significantly higher total rate for enzalutamide and the other finding no significant difference, a discrepancy likely driven by different study pools and statistical methods. Neither drug showed a clear edge on perceived cognitive impairments, a concern often raised by patients. In practice, the choice between them often comes down to a patient’s baseline cardiovascular health, tolerance for fatigue, and the need for concomitant prednisone (which abiraterone requires but enzalutamide does not).

The Food Effect and a Potential Cost-Saving Trick

One of abiraterone’s quirks is a dramatic “food effect.” When the standard dose is taken on an empty stomach, as the label recommends, absorption is relatively modest. But when taken with a meal, especially one high in fat, absorption skyrockets. This pharmacokinetic property has led researchers to ask an obvious question: could a much lower dose taken with food achieve the same results as the full dose on an empty stomach?

A prospective randomized trial tested exactly this, comparing a quarter of the standard dose taken with a low-fat breakfast against the standard dose on an empty stomach. The low-dose arm was not inferior by predefined criteria: PSA response rates were 58% versus 50%, and median progression-free survival was about nine months in both groups, despite the low-dose arm costing a fraction of the price.¹⁷ Abiraterone blood concentrations were actually higher in the standard-dose arm, but this did not translate into better cancer control.

The financial implications are significant. A study of out-of-pocket costs within that same trial found that the average monthly cost for patients on the low-dose arm was about $44, compared with roughly $394 for the standard-dose arm. More telling, adherence to therapy was moderately better with the lower-cost regimen, with patients on the standard dose showing a significant drop in adherence over time that was not seen in the low-dose group.¹⁸ Low-dose-with-food strategies remain attractive in settings where cost is a barrier to treatment, though large confirmatory trials are still needed before this approach becomes standard in high-resource healthcare systems.¹⁹

When the Drug Stops Working

Resistance to abiraterone is, unfortunately, inevitable. The question is usually when, not if. Understanding the mechanisms behind resistance matters because it shapes what treatment comes next.

One major pathway involves the androgen receptor itself. Tumors can upregulate production of CYP17A1, essentially outpacing the drug’s ability to block it, or the cancer cells can produce truncated forms of the androgen receptor known as splice variants. The most studied of these, called AR-V7, lacks the part of the receptor where androgens (and abiraterone’s metabolites) bind. That means AR-V7 can switch on tumor-growth genes without needing any hormonal signal at all, making androgen-directed therapies largely useless against it.²⁰

Clinical data bear this out starkly. In one study, patients whose circulating tumor cells expressed AR-V7 had a 0% PSA response rate to abiraterone, compared with 68% in AR-V7-negative patients. Median progression-free survival was about 2.3 months versus not yet reached, and overall survival was roughly 10.6 months versus not yet reached.²¹ The good news is that AR-V7-positive tumors appear to retain sensitivity to taxane chemotherapy, which attacks cancer cells through an entirely different mechanism.²²

Beyond splice variants, long-term exposure to abiraterone has been linked to overexpression of the glucocorticoid receptor, which may enable cancer cells to hijack a parallel signaling pathway to keep growing.²³ There is also evidence of cross-resistance between abiraterone and enzalutamide, meaning that using one drug first can reduce the effectiveness of the other. Preclinical work has demonstrated impaired efficacy of enzalutamide, docetaxel, and cabazitaxel in abiraterone-resistant cell lines, and the reverse has been observed as well.²⁴ This is why treatment sequencing, the order in which drugs are given, is a major topic of debate in oncology boardrooms.²⁵

Combining Abiraterone With PARP Inhibitors

One of the more exciting developments is pairing abiraterone with PARP inhibitors, drugs like olaparib that exploit defects in a tumor’s ability to repair its own DNA. The PROpel trial demonstrated that adding olaparib to abiraterone significantly improved radiographic progression-free survival as a first-line treatment for castration-resistant disease, and this benefit held across patients regardless of whether their tumors carried specific DNA repair mutations.²⁶

A real-world multicenter study looked at the same combination in patients who had already progressed on abiraterone and who harbored DNA damage repair defects. The combination of olaparib plus abiraterone roughly doubled progression-free survival compared with olaparib alone (6 months versus 3 months) and more than doubled overall survival (25 months versus 12 months).²⁷ These combinations are reshaping treatment algorithms, particularly for the subset of patients whose tumors have identifiable genetic vulnerabilities.

Cost, Generics, and Access

Abiraterone was initially expensive, and drug cost shaped real-world treatment decisions for years. Between 2013 and 2018, Medicare spending on all abiraterone formulations climbed from $470 million to $1.5 billion, with the annual per-patient cost approaching $49,000 at its peak. Generic versions became available in 2018, and the landscape shifted rapidly. By 2023, the annual cost per patient had dropped to under $20,000, and the number of Medicare beneficiaries receiving the drug had more than tripled, rising from about 14,000 to over 46,000 per year. Total Medicare savings attributed to generic adoption from 2018 to 2023 amounted to roughly $7.3 billion.²⁸

Cost matters beyond sticker price because it influences whether patients stay on their medication. The adherence data from the food-effect trial showed a correlation between lower out-of-pocket spending and better adherence, a pattern oncologists see across many oral cancer drugs. When a treatment requires daily pills for months or years, even modest financial friction can erode compliance.

Kidney Disease and Other Special Populations

A common concern for older cancer patients is whether their kidneys can handle a new drug. Pharmacokinetic studies have addressed this directly. In patients with end-stage renal disease on dialysis, a single dose of abiraterone showed no meaningful increase in drug exposure compared with people who had normal kidney function. The drug was well tolerated, with no serious adverse events reported in the renal impairment group.²⁹ This means kidney impairment generally does not require dose adjustment, though liver function is a different matter: patients with moderate-to-severe liver problems need more careful evaluation before starting treatment.

Bone Health in Patients on Abiraterone

Fractures are a persistent concern in prostate cancer patients because hormone therapy accelerates bone loss. A secondary analysis of two large trials within the STAMPEDE platform examined whether adding abiraterone to standard care changed fracture-related hospitalization rates. In patients with cancer that had not spread beyond the prostate and nearby lymph nodes, there was no difference. In patients with metastatic disease, however, adding abiraterone actually reduced fracture-related hospitalizations, with a five-year cumulative incidence of about 22% compared with 30% in the standard-care group.³⁰ The likely explanation is that abiraterone’s superior cancer control in metastatic patients reduces skeletal events driven by the cancer itself, offsetting any bone-weakening effect of deeper hormone suppression.

Research Beyond Prostate Cancer

Because the androgen receptor is not exclusive to prostate tissue, researchers have tested abiraterone in other cancers that express it. A phase II trial treated patients with androgen receptor-expressing salivary gland cancers that had stopped responding to standard hormone therapy. The overall response rate was 21%, with disease control achieved in over 60% of patients. While modest by prostate cancer standards, these results are meaningful for a rare cancer type with few second-line options.³¹ Early-stage work has also explored abiraterone’s potential relevance to androgen receptor-positive breast cancer and other hormone-driven malignancies, though none of these indications has progressed to the point of regulatory approval.